Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles R Esther

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Pediatric Pulmonology|July 18, 2017
Mapping targetable inflammation and outcomes with cystic fibrosis biomarkersOlivia Giddings, Charles R Esther
Pediatric Pulmonology|August 31, 2004
Pulmonary lymphangiectasia: diagnosis and clinical courseCharles R Esther, Pierre M Barker
Current Opinion in Pharmacology|June 1, 2022
Metabolomics of airways disease in cystic fibrosisJoshua D Chandler, Charles R Esther
American Journal of Respiratory and Critical Care Medicine|August 28, 2019
Identifying Biomarkers in Pediatric Rare Lung Disease. chILD Grows UpTimothy J Vece, Charles R Esther
Infection Control and Hospital Epidemiology|March 3, 2015
Detection of Mycobacterium abscessus from deep pharyngeal swabs in cystic fibrosisCharles R Esther, Alan Kerr, Peter H Gilligan
Expert Review of Precision Medicine and Drug Development|August 3, 2016
Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutationDeborah M Cholon, Charles R Esther, Martina Gentzsch
Pediatric Pulmonology|February 18, 2011
Impact of an evidence-based algorithm on quality of care in pediatric parapneumonic effusion and empyemaKyrie L Shomaker, Tim Weiner, Charles R Esther
Sub-Cellular Biochemistry|May 12, 2011
Regulation of airway nucleotides in chronic lung diseasesCharles R Esther, Neil E Alexis, Maryse Picher
Journal of Breath Research|December 16, 2017
Transition and post-transition metals in exhaled breath condensateAndrew J Ghio, Michael C Madden, Charles R Esther
The Lancet. Respiratory Medicine|October 12, 2024
Airway inflammation enhances the effectiveness of elexacaftor-tezacaftor-ivacaftor therapy for cystic fibrosis and CFTR<sup>N1303K</sup> mutationMartina Gentzsch, Charles R Esther, Carla M P Ribeiro
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Pediatric Pulmonology|July 18, 2017
Mapping targetable inflammation and outcomes with cystic fibrosis biomarkersOlivia Giddings, Charles R Esther
Pediatric Pulmonology|August 31, 2004
Pulmonary lymphangiectasia: diagnosis and clinical courseCharles R Esther, Pierre M Barker
Current Opinion in Pharmacology|June 1, 2022
Metabolomics of airways disease in cystic fibrosisJoshua D Chandler, Charles R Esther
American Journal of Respiratory and Critical Care Medicine|August 28, 2019
Identifying Biomarkers in Pediatric Rare Lung Disease. chILD Grows UpTimothy J Vece, Charles R Esther
Infection Control and Hospital Epidemiology|March 3, 2015
Detection of Mycobacterium abscessus from deep pharyngeal swabs in cystic fibrosisCharles R Esther, Alan Kerr, Peter H Gilligan
Expert Review of Precision Medicine and Drug Development|August 3, 2016
Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutationDeborah M Cholon, Charles R Esther, Martina Gentzsch
Pediatric Pulmonology|February 18, 2011
Impact of an evidence-based algorithm on quality of care in pediatric parapneumonic effusion and empyemaKyrie L Shomaker, Tim Weiner, Charles R Esther
Sub-Cellular Biochemistry|May 12, 2011
Regulation of airway nucleotides in chronic lung diseasesCharles R Esther, Neil E Alexis, Maryse Picher
Journal of Breath Research|December 16, 2017
Transition and post-transition metals in exhaled breath condensateAndrew J Ghio, Michael C Madden, Charles R Esther
The Lancet. Respiratory Medicine|October 12, 2024
Airway inflammation enhances the effectiveness of elexacaftor-tezacaftor-ivacaftor therapy for cystic fibrosis and CFTR<sup>N1303K</sup> mutationMartina Gentzsch, Charles R Esther, Carla M P Ribeiro
Pageof 11